Inmed Pharmaceuticals Inc (INM)

$0.82 -0.06 (-6.82%)
Market Cap 2.57M
Revenue (ttm) 4.94M
Net Income (ttm) -8.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -165.18%
Debt to Equity Ratio 0.00
Volume 93,700
Avg Vol 82,886
Day's Range N/A - N/A
Shares Out 2.92M
Stochastic %K 35%
Beta 0.42
Analysts Strong Buy
Price Target $45.00

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its pres...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 604 669 7207
Fax: 778 945 6800
Address:
885 West Georgia Street, Suite 1445, Vancouver, Canada
BadBankofGotham
BadBankofGotham Mar. 19 at 4:03 PM
$INM Hmm why does it drop this makes no sense
0 · Reply
alfredaita
alfredaita Mar. 18 at 6:21 PM
$INM good conference but not much said about partner shopping particularly for their cream product
0 · Reply
ArcticFoxx
ArcticFoxx Mar. 16 at 8:52 PM
\\@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. \If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $ARAY $INTZ $QTI $INM >>> on watch.
0 · Reply
Space0
Space0 Mar. 16 at 8:39 PM
$INM this is so good, I think we will hear some good news
0 · Reply
AlwaysLearning72
AlwaysLearning72 Mar. 16 at 1:47 PM
$INM that was a nice 15K volume green candle to start the day up 8%. 🙂. That shows how thin this is and how fast it could move up on positive news
0 · Reply
AlwaysLearning72
AlwaysLearning72 Mar. 16 at 1:45 PM
$INM nice green day for small caps. Hopefully we get some positive news here and see a nice run.
0 · Reply
Parobull
Parobull Mar. 9 at 9:28 PM
$POLA break 1.85 and this explodes $TURB $INM $OPEN
0 · Reply
newsfile_corp
newsfile_corp Mar. 9 at 11:32 AM
https://nfne.ws/287694 $INM @inmedpharma #Alzheimher39s #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NA
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 9 at 11:32 AM
$INM = INM InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
0 · Reply
focafoca99
focafoca99 Mar. 7 at 11:36 PM
$INM said new legislation would hit BayMedica hard, and the board is moving to wind it down
0 · Reply
Latest News on INM
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Mar 9, 2026, 7:30 AM EDT - 10 days ago

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

Mar 6, 2026, 5:04 PM EST - 13 days ago

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Feb 11, 2026, 5:23 PM EST - 5 weeks ago

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

Dec 17, 2025, 8:59 PM EST - 3 months ago

InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

InMed Announces Results of 2025 Annual General and Special Meeting

Dec 17, 2025, 8:00 PM EST - 3 months ago

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Provides Update on BayMedica Commercial Business

Dec 12, 2025, 5:31 PM EST - 3 months ago

InMed Provides Update on BayMedica Commercial Business

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Nov 18, 2025, 7:30 AM EST - 4 months ago

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:51 PM EST - 4 months ago

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Oct 16, 2025, 8:30 AM EDT - 5 months ago

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 5 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

ZYME

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 23, 2025, 8:30 AM EDT - 6 months ago

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Sep 16, 2025, 1:39 PM EDT - 6 months ago

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 1:33 PM EDT - 6 months ago

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jul 28, 2025, 7:00 AM EDT - 8 months ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 27, 2025, 7:00 AM EDT - 9 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 25, 2025, 8:00 AM EDT - 9 months ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 24, 2025, 7:00 AM EDT - 9 months ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

Jun 13, 2025, 4:30 PM EDT - 9 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025, 6:00 PM EDT - 11 months ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 6:54 PM EST - 1 year ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Feb 3, 2025, 7:30 AM EST - 1 year ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 22, 2025, 7:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Jan 21, 2025, 7:30 AM EST - 1 year ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

InMed Announces Results of 2024 Annual General Meeting

Dec 18, 2024, 8:00 PM EST - 1 year ago

InMed Announces Results of 2024 Annual General Meeting

InMed Enters Into Standby Equity Purchase Agreement

Dec 17, 2024, 4:56 PM EST - 1 year ago

InMed Enters Into Standby Equity Purchase Agreement

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 19, 2024, 7:30 AM EST - 1 year ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 14, 2024, 4:45 PM EST - 1 year ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 8, 2024, 4:44 PM EST - 1 year ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Nov 5, 2024, 8:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 28, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 1 year ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Oct 22, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Sep 20, 2024, 4:30 PM EDT - 1 year ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 10:10 AM EDT - 1 year ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

InMed to Present at the Emerging Growth Conference

Jun 10, 2024, 5:18 PM EDT - 1 year ago

InMed to Present at the Emerging Growth Conference

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024, 8:30 AM EDT - 2 years ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 18, 2024, 8:00 AM EDT - 2 years ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 16, 2024, 8:00 AM EDT - 2 years ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Apr 4, 2024, 8:00 AM EDT - 2 years ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Mar 20, 2024, 8:30 AM EDT - 2 years ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 13, 2024, 5:41 PM EST - 2 years ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Feb 9, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 18, 2024, 4:41 PM EST - 2 years ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Jan 16, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Announces Results of 2023 Annual General Meeting

Dec 19, 2023, 6:03 PM EST - 2 years ago

InMed Announces Results of 2023 Annual General Meeting

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Nov 14, 2023, 8:04 AM EST - 2 years ago

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

BadBankofGotham
BadBankofGotham Mar. 19 at 4:03 PM
$INM Hmm why does it drop this makes no sense
0 · Reply
alfredaita
alfredaita Mar. 18 at 6:21 PM
$INM good conference but not much said about partner shopping particularly for their cream product
0 · Reply
ArcticFoxx
ArcticFoxx Mar. 16 at 8:52 PM
\\@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. \If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $ARAY $INTZ $QTI $INM >>> on watch.
0 · Reply
Space0
Space0 Mar. 16 at 8:39 PM
$INM this is so good, I think we will hear some good news
0 · Reply
AlwaysLearning72
AlwaysLearning72 Mar. 16 at 1:47 PM
$INM that was a nice 15K volume green candle to start the day up 8%. 🙂. That shows how thin this is and how fast it could move up on positive news
0 · Reply
AlwaysLearning72
AlwaysLearning72 Mar. 16 at 1:45 PM
$INM nice green day for small caps. Hopefully we get some positive news here and see a nice run.
0 · Reply
Parobull
Parobull Mar. 9 at 9:28 PM
$POLA break 1.85 and this explodes $TURB $INM $OPEN
0 · Reply
newsfile_corp
newsfile_corp Mar. 9 at 11:32 AM
https://nfne.ws/287694 $INM @inmedpharma #Alzheimher39s #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NA
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 9 at 11:32 AM
$INM = INM InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
0 · Reply
focafoca99
focafoca99 Mar. 7 at 11:36 PM
$INM said new legislation would hit BayMedica hard, and the board is moving to wind it down
0 · Reply
newsfile_corp
newsfile_corp Mar. 6 at 10:05 PM
https://nfne.ws/286536 $INM @inmedpharma #cannabinoids #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NAS
0 · Reply
sbn15
sbn15 Mar. 4 at 10:08 PM
$INM movement ...
0 · Reply
PaulLaurent
PaulLaurent Mar. 4 at 8:08 PM
📢📊 Unusual Volume Stocks 📊📢 $DSTX $OKTG $ADVB $RFEM $INM
0 · Reply
Bullsarmy
Bullsarmy Mar. 4 at 6:16 PM
$INM Inm I'm out Always take your profit😉
0 · Reply
topstockalerts
topstockalerts Mar. 4 at 6:01 PM
$INM base forming with steady accumulation after insider buys hit the ticker; liquidity drying up near support and traders watching tape.
0 · Reply
aw20
aw20 Mar. 4 at 3:21 PM
$INM oversold. could squeeze to 1.20-1.50 👀 @DaBullRunner
0 · Reply
MiWo85
MiWo85 Mar. 4 at 3:18 PM
$INM please do an $EDSA run next!
0 · Reply
aw20
aw20 Mar. 4 at 2:59 PM
$INM 👀👀 grabbed some lotto yesterday at 0.75. Let's see
0 · Reply
Getthismoney101
Getthismoney101 Mar. 4 at 2:50 PM
$FCHL average holder has a price of 3.97!!!!! We are currently at .21 with no dilution and only 5m free float shares! 65% insider ownership. Still in 180 day lockup period. 40k shares available. Gaps up to 6 bucks !!🤫🚀 $AIB $DLXY $INM
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 26 at 3:53 AM
$INM Current Stock Price: $0.89
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 11:42 PM
$INM RSI: 34.06, MACD: -0.0716 Vol: 0.09, MA20: 0.95, MA50: 1.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PenkeInvesting
PenkeInvesting Feb. 25 at 9:54 PM
Fundamental analysis of $INM (InMed Pharmaceuticals Inc.) based on financial data and reported results. #INM #InMed
0 · Reply